BioSpace News Archive

Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis

Company further expands its global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid the treatment of patients with cancer

Health plans are playing a leadership role in combatting the nation’s opioid crisis due to growing concerns around medication misuse, addiction and overdoses. To help health insurance providers in these efforts, DisposeRx, Inc ., the product leader in at-home medication disposal solutions, has created a new education and engagement pr

Lincotek Medical – one of the leading global providers of products and services to orthopaedic original equipment manufacturers – has recently installed new state-of-the-art equipment to respond to ever-more demanding customer requirements in terms of design and dimensional specifications. The move is an essential part of the company’s strategy to deliver co

Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with met

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part of the annual reconstitution of the Russell stock indexes, DermTech has been selected to be added to the Russell 2000 ® Index effective June 26, 2020. “We are pleased to have earned our inclusion in the Russell 2000 ® Index, one of the most widely cited perfo

At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet - - DaxibotulinumtoxinA for Injection was well tolerated across all doses in both indications - NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, i

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the closing of an oversubscribed Series B financing, which rais

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy Mahatme, Sarepta’s executive vice president, chief financial officer and chief business officer, from the company effective July 10, 2020. The company has commenced a search process to identify the future chief financial officer. During the interim period, the finance and accounting functions will repor

Advanced data visualization company Zoic Labs has partnered with The Krogan Lab, a world-renowned scientific research unit at Quantitative Biosciences Institute (QBI) at the UC San Francisco, to